Rigetti Computing Inc vs Sana Biotechnology Inc — how do they compare? Rigetti Computing Inc trades at $15.33 (market cap $5.28B), while Sana Biotechnology Inc trades at $3.24 (market cap $1.03B). The key difference: Rigetti Computing Inc is far larger — about 5.1× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Rigetti Computing Inc nearer its low. Which is the better fit depends on your goals.
| RGTI | SANA | |
|---|---|---|
Market Cap | $5.28B | $1.03B |
Sector | Technology | Health |
52-Week High | $56.34 | $5.92 |
52-Week Low | $12.90 | $2.68 |
Enterprise Value | $4.89B | $946.04M |
Signals from Pluang's Aura AI — not financial advice
Rigetti Computing (RGTI) trades at $15.81, up 4.01% today, amid mixed signals with bearish technical indicators but strong analyst support. The stock shows significant fundamental challenges with a P/S ratio of 391.11 and deeply negative profit margins (-1,787.4% net income margin), though recent government funding of $100 million provides crucial support. Technical analysis indicates bearish momentum with support at $15 and resistance at $17.
The outlook remains speculative with substantial execution risks and widening losses, offset by government backing and quantum computing potential. Investment opportunity hinges on long-term technology commercialization, while immediate risks include persistent cash burn and competitive pressures in the nascent quantum sector.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Trailing returns across standard periods
Latest headlines on both assets
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →